Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
A8MTZ0

UPID:
BBIP1_HUMAN

ALTERNATIVE NAMES:
BBSome-interacting protein of 10 kDa

ALTERNATIVE UPACC:
A8MTZ0; E9PIY9; E9PM41; E9PRI7

BACKGROUND:
BBSome-interacting protein 1, with its alternative name BBSome-interacting protein of 10 kDa, is essential for primary cilia assembly and BBSome stability. It facilitates the sorting of membrane proteins to primary cilia, a process crucial for cell signaling and development, by mediating the function of the Rab8 GDP/GTP exchange factor.

THERAPEUTIC SIGNIFICANCE:
The involvement of BBSome-interacting protein 1 in Bardet-Biedl syndrome 18, characterized by a spectrum of symptoms including early-onset obesity and renal malformation, underscores the therapeutic potential of targeting this protein in disease management and treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.